Abstract: To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-?-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.

Abstract: Provided is an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and may be used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains a compound selected from a cyclolanostane compound and a lophenol compound as an active ingredient.

Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.

Abstract: A technique for efficiently performing pulverization of a dried aloe gel using an air flow type mill is provided. 1) A dried aloe gel is treated by supercritical extraction, an extract is removed from the dried aloe gel to obtain an extraction residue, and then 2) the extraction residue is pulverized with an air flow type mill to produce an aloe powder.

Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.

Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.

Abstract: Provided is an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and may be used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains a compound selected from a cyclolanostane compound and a lophenol compound as an active ingredient.

Abstract: To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-?-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient.

Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.

Abstract: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing ?-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein ?-casein accounts for 60% by mass or more of the milk-derived casein.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: (A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2; (B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: (A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2; (B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: (A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2; (B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

Abstract: Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof: